Analysis of outcome by response flawed [5]

Journal of Clinical Oncology

Volumn 23, Issue 31, 2005, Pages 8122-8123

  Anderson, James R ^a   Neuberg, Donna S ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT;

B CELL LEUKEMIA; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; HUMAN; LETTER; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT REFUSAL; BONE MARROW; DISEASE FREE SURVIVAL; NOTE; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE MARROW; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASM, RESIDUAL; TREATMENT OUTCOME;

EID: 32944455439     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.0148     Document Type: Letter

References (2)

1. Moreton P, Kennedy B, Lucas G, et al: Eradication of minimal residual disease in B-Cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971-2979, 2005
2. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983